Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $46.67.

Several research analysts have recently issued reports on NBTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, October 15th. Guggenheim started coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company.

Nanobiotix Price Performance

Shares of NBTX stock opened at $32.03 on Tuesday. The business’s 50-day moving average price is $31.00 and its 200-day moving average price is $33.99. Nanobiotix has a 12 month low of $19.14 and a 12 month high of $57.14.

About Nanobiotix

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy.

Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.